6 days ago
1
- Micro-cap cancer drug developer IGM Biosciences (NASDAQ:IGMS) added ~21% after Concentra Biosciences agreed to acquire the company for $1.247 in cash upfront plus a non-tradeable contingent value right (CVR) per share.
- Under the terms, Concentra, an entity controlled by hedge fund Tang
English (US) ·